Technologies for controlled, local delivery of siRNA

Journal of Controlled Release

Volumn 218, Issue , 2015, Pages 94-113

  Sarett, Samantha M ^a   Nelson, Christopher E ^b   Duvall, Craig L ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b Duke University   (United States)

Author keywords

Gene silencing; Local delivery; siRNA

Indexed keywords

CHEMICAL MODIFICATION; GENETIC ENGINEERING;

CLINICAL TRANSLATION; DESIGN CONSIDERATIONS; GENE SILENCING; LOCAL DELIVERY; MECHANISM OF ACTION; SIRNA; SUSTAINED RELEASE; SYSTEMIC DELIVERIES;

GENES;

MOLECULAR SCAFFOLD; SMALL INTERFERING RNA;

ANGIOGENESIS; ARTICLE; DRUG DELIVERY SYSTEM; GENE SILENCING; HUMAN; HYDROGEL; INFLAMMATION; LOCAL THERAPY; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; RNA TRANSLATION; SUSTAINED DRUG RELEASE; TARGET ORGAN; TISSUE REGENERATION; WOUND HEALING; PHARMACEUTICS;

GENE SILENCING; RNA, SMALL INTERFERING; TECHNOLOGY, PHARMACEUTICAL;

EID: 84945196020     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.09.066     Document Type: Review

References (227)

1. R.W. Carthew, and E.J. Sontheimer Origins and mechanisms of miRNAs and siRNAs Cell 136 2009 642 655
2. Y. Yao, C. Wang, R.R. Varshney, and D.A. Wang Antisense makes sense in engineered regenerative medicine Pharm. Res. 26 2009 263 275
3. K. Sliva, and B.S. Schnierle Selective gene silencing by viral delivery of short hairpin RNA Virology 7 2010 248
4. D.W. Bartlett, and M.E. Davis Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging Nucleic Acids Res. 34 2006 322 333
5. D.M. Dykxhoorn, D. Palliser, and J. Lieberman The silent treatment: SiRNAs as small molecule drugs Gene Ther. 13 2006 541 552
6. H. Yin, R.L. Kanasty, A.A. Eltoukhy, A.J. Vegas, J.R. Dorkin, and D.G. Anderson Non-viral vectors for gene-based therapy Nat. Rev. Gen. 15 2014 541 555
7. T. Coelho, D. Adams, A. Silva, P. Lozeron, P.N. Hawkins, T. Mant, J. Perez, J. Chiesa, S. Warrington, E. Tranter, M. Munisamy, R. Falzone, J. Harrop, J. Cehelsky, B.R. Bettencourt, M. Geissler, J.S. Butler, A. Sehgal, R.E. Meyers, Q. Chen, T. Borland, R.M. Hutabarat, V.A. Clausen, R. Alvarez, K. Fitzgerald, C. Gamba-Vitalo, S.V. Nochur, A.K. Vaishnaw, D.W. Sah, J.A. Gollob, and O.B. Suhr Safety and efficacy of RNAi therapy for transthyretin amyloidosis New Engl. J. Med. 369 2013 819 829
8. D. Haussecker Current issues of RNAi therapeutics delivery and development J. Control Release 195 2014 49 54
9. J.E. Zuckerman, T. Hsueh, R.C. Koya, M.E. Davis, and A. Ribas SiRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide J. Invest. Dermatol. 131 2011 453 460
10. M. Yasuda, L. Gan, B. Chen, S. Kadirvel, C. Yu, J.D. Phillips, M.I. New, A. Liebow, K. Fitzgerald, W. Querbes, and R.J. Desnick RNAi-mediated silencing of hepatic ALAS1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice Proc. Natl. Acad. Sci. U.S.A. 111 2014 7777 7782
11. Alnylam RNAi roundtable: conjugate delivery 2012
12. D. Haussecker The business of RNAi therapeutics in 2012 Mol. Ther. Nucleic Acids 1 2012 e8
13. H.Y. Xue, S. Liu, and H.L. Wong Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine Nanomed 9 2014 295 312
14. M.E. Kleinman, K. Yamada, A. Takeda, V. Chandrasekaran, M. Nozaki, J.Z. Baffi, R.J. Albuquerque, S. Yamasaki, M. Itaya, Y. Pan, B. Appukuttan, D. Gibbs, Z. Yang, K. Kariko, B.K. Ambati, T.A. Wilgus, L.A. DiPietro, E. Sakurai, K. Zhang, J.R. Smith, E.W. Taylor, and J. Ambati Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 Nature 452 2008 591 597
15. T. Inoue, M. Sugimoto, T. Sakurai, R. Saito, N. Futaki, Y. Hashimoto, Y. Honma, I. Arai, and S. Nakaike Modulation of scratching behavior by silencing an endogenous cyclooxygenase-1 gene in the skin through the administration of siRNA J. Gene. Med. 9 2007 994 1001
16. C. Napoli, C. Lemieux, and R. Jorgensen Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes ín trans Plant Cell 2 1990
17. J. Bertrand, M. Pottier, A. Vekris, P. Opolon, A. Maksimenko, and C. Malvy Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo Biochem. Biophys. Res. Commun. 296 2002
18. D.H. Kim, M.A. Behlke, S.D. Rose, M.S. Chang, S. Choi, and J.J. Rossi Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy Nat. Biotechnol. 23 2005 222 226
19. B.F. Baker 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells J. Biol. Chem. 272 1997 11994 12000
20. S.M. Hammond, E. Bernstein, D. Beach, and G.J. Hannon An RNA-directed nuclease mediates post-transcriptional gene silencing in drosophila cells Nature 404 2000
21. E. Bernstein, A.A. Caudy, S.M. Hammond, and G.J. Hannon Role for a bidentate ribonuclease in the initiation step of RNA interference Nature 409 2001
22. B. Haley, and P.D. Zamore Kinetic analysis of the RNAi enzyme complex Nat. Struct. Biol. 11 2004 599 606
23. K.R. Beavers, C.E. Nelson, and C.L. Duvall MiRNA inhibition in tissue engineering and regenerative medicine Adv. Drug Deliv. Rev. 88 2014 123 137
24. K.A. Whitehead, R. Langer, and D.G. Anderson Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discov. 8 2009 129 138
25. M.A. Behlke Chemical modification of siRNAs for in vivo use Oligonucleotides 18 2008 305 319
26. J. Martinez, A. Patkaniowska, H. Urlaub, R. Luhrmann, and T. Tuschl Single-stranded antisense siRNAs guide target RNA cleavage in RNAi Cell 110 2004
27. J. Gilleron, W. Querbes, A. Zeigerer, A. Borodovsky, G. Marsico, U. Schubert, K. Manygoats, S. Seifert, C. Andree, M. Stoter, H. Epstein-Barash, L. Zhang, V. Koteliansky, K. Fitzgerald, E. Fava, M. Bickle, Y. Kalaidzidis, A. Akinc, M. Maier, and M. Zerial Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape Nat. Biotechnol. 31 2013 638 646
28. S.M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411 2001
29. K. Kariko, P. Bhuyan, J. Capodici, and D. Weissman Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3 J. Immunol. 172 2004 6545 6549
30. F. Heil, H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8 Science 303 2004
31. A.L. Jackson, and P.S. Linsley Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application Nat. Rev. Drug Discov. 9 2010 57 67
32. J.E. Zuckerman, I. Gritli, A. Tolcher, J.D. Heidel, D. Lim, R. Morgan, B. Chmielowski, A. Ribas, M.E. Davis, and Y. Yen Correlating animal and human phase IA/IB clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA Proc. Natl. Acad. Sci. U. S. A. 111 2014 11449 11454
33. R. Yi, B.P. Doehle, Y. Qin, I.G. Macara, and B.R. Cullen Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs RNA 11 2005 220 226
34. A.L. Jackson, S.R. Bartz, J. Schelter, S.V. Kobayashi, J. Burchard, M. Mao, B. Li, G. Cavet, and P.S. Linsley Expression profiling reveals off-target gene regulation by RNAi Nat. Biotechnol 2003
35. F.T. Vicentini, L.N. Borgheti-Cardoso, L.V. Depieri, M.D. de Macedo, T.F. Abelha, R. Petrilli, and M.V. Bentley Delivery systems and local administration routes for therapeutic siRNA Pharm. Res. 30 2013 915 931
36. A. Sadio, J.K. Gustafsson, B. Pereira, C.P. Gomes, G.C. Hansson, L. David, A.P. Pego, and R. Almeida Modified-chitosan/siRNA nanoparticles downregulate cellular cdx2 expression and cross the gastric mucus barrier PloS One 9 2014
37. J.R. Weiser, and W.M. Saltzman Controlled release for local delivery of drugs: barriers and models J. Control Release 190 2014 664 673
38. L.A. Wheeler, V. Vrbanac, R. Trifonova, M.A. Brehm, A. Gilboa-Geffen, S. Tanno, D.L. Greiner, A.D. Luster, A.M. Tager, and J. Lieberman Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras Mol. Ther. 21 2013 1378 1389
39. C.E. Nelson, A.J. Kim, E.J. Adolph, M.K. Gupta, F. Yu, K.M. Hocking, J.M. Davidson, S.A. Guelcher, and C.L. Duvall Tunable delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo Adv. Mat. 26 2014 607 614 506
40. J.M. Layzer In vivo activity of nuclease-resistant siRNAs RNA 10 2004 766 771
41. M. Dimitrova, C. Affolter, F. Meyer, I. Nguyen, D.G. Richard, C. Schuster, R. Bartenschlager, J.C. Voegel, J. Ogier, and T.F. Baumert Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films Proc. Natl. Acad. Sci. U. S. A. 105 2008 16320 16325
42. L.D. Laporte, and L.D. Shea Matrices and scaffolds for DNA delivery in tissue engineering Adv. Drug Deliv. Rev. 59 2007
43. M. Chen, S. Gao, M. Dong, J. Song, C. Yang, K.A. Howard, J. Kjems, and F. Besenbacher Chitosan/siRNA nanoparticles encapsulated in PLGA nanofibers for siRNA delivery ACS Nano 6 2012
44. D. Klose, F. Siepmann, K. Elkharraz, S. Krenzlin, and J. Siepmann How porosity and size affect the drug release mechanisms from PLGA-based microparticles Int. J. Pharm. 314 2006 198 206
45. H.H.D. Tai, S. Takae, W. Wang, T. Vermonden, E.W. Hennink, P.S. Stayton, A.S. Hoffman, A. Endruweit, C. Alexander, S.M. Howdle, and K.M. Shakesheff Photo-cross-linked hydrogels from thermoresponsive PEGMEMA-PPGMA-EGDMA copolymers containing multiple methacrylate groups: mechanical property, swelling, protein release, cytotoxicity Biomacromolecules 10 2009 2895 2903
46. B.K.G.A. Mann, A.T. Tsai, R.H. Schmelen, and J.L. West Smooth muscle cell growth in photopolymerized hydrogels with cell adhesive and proteolytically degradable domains: synthetic ECM analogs for tissue engineering Biomaterials 22 2001
47. J.L. West, and J.A. Hubbell Polymeric biomaterials with degradation sites for proteases involved in cell migration Macromolecules 32 1999
48. P.X. Ma Biomimetic materials for tissue engineering Adv. Drug. Deliv. Rev. 60 2008 184 198
49. L.D. Shea, E. Smiley, J. Bonadio, and D.J. Mooney DNA delivery from polymer matrices for tissue engineering Nat. Biotechnol. 17 1999
50. G. De Rosa, M.C. Maiuri, F. Ungaro, D. De Stefano, F. Quaglia, M.I. La Rotonda, and R. Carnuccio Enhanced intracellular uptake and inhibition of NF-κβ activation by decoy oligonucleotide released from PLGA microspheres J. Gene Med. 7 2005
51. T. Estey, J. Kang, S.P. Schwendeman, and J.F. Carpenter BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems J. Pharm. Sci. 95 2006 1626 1639
52. R.P. Felix Lanao, S.C. Leeuwenburgh, J.G. Wolke, and J.A. Jansen In vitro degradation rate of apatitic calcium phosphate cement with incorporated PLGA microspheres Acta Biomater. 7 2011 3459 3468
53. J.R. Martin, M.K. Gupta, J.M. Page, F. Yu, J.M. Davidson, S.A. Guelcher, and C.L. Duvall A porous tissue engineering scaffold selectively degraded by cell-generated reactive oxygen species Biomaterials 35 2014 3766 3776
54. D.S. Wilson, G. Dalmasso, L. Wang, S.V. Sitaraman, D. Merlin, and N. Murthy Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines Nat. Mater. 9 2010
55. T. Segura, and L.D. Shea Surface-tethered DNA complexes for enhanced gene delivery Bioconjug. Chem. 13 2002
56. M. Amarzguioui, T. Holen, E. Babaie, and H. Prydz Tolerance for mutations and chemical modications in a siRNA Nucleic Acids Res. 31 2003
57. D.A. Braasch, S. Jensen, Y. Liu, K. Kaur, K. Arar, M.A. White, and D.R. Corey RNA interference in mammalian cells by chemically-modified RNA Biochemistry 42 2003
58. A. Judge, and I. MacLachlan Overcoming the innate immune response to small interfering RNA Hum. Gene Ther. 19 2008 111 124
59. Y.L. Chiu SiRNA function in RNAi: a chemical modification analysis RNA 9 2003 1034 1048
60. J. Wang, Z. Lu, M.G. Wientjes, and J.L. Au Delivery of siRNA therapeutics: barriers and carriers AAPS J. 12 2010 492 503
61. J.H. Jeong, H. Mok, Y. Oh, and T.G. Park SiRNA conjugate delivery systems Bioconjug. Chem. 20 2009 5 14
62. R. Kanasty, J.R. Dorkin, A. Vegas, and D. Anderson Delivery materials for siRNA therapeutics Nat. Mater. 12 2013
63. T. Kubo, Y. Takei, K. Mihara, K. Yanagihara, and T. Seyama Amino-modified and lipid-conjugated dicer-substrate siRNA enhances RNAi efficacy Bioconjug. Chem. 23 2012 164 173
64. K. Nishina, T. Unno, Y. Uno, T. Kubodera, T. Kanouchi, H. Mizusawa, and T. Yokota Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol Mol. Ther. 16 2008 734 740
65. S.Y. Wu, and N.A. McMillan Lipidic systems for in vivo siRNA delivery AAPS J. 11 2009 639 652
66. K.G. Rajeev, J.K. Nair, M. Jayaraman, K. Charisse, N. Taneja, J. O'Shea, J.L. Willoughby, K. Yucius, T. Nguyen, S. Shulga-Morskaya, S. Milstein, A. Liebow, W. Querbes, A. Borodovsky, K. Fitzgerald, M.A. Maier, and M. Manoharan Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo Chembiochem 16 2015 903 908
67. S. Matsuda, K. Keiser, J.K. Nair, K. Charisse, R.M. Manoharan, P. Kretschmer, C.G. Peng, A. VKi, P. Kandasamy, J.L. Willoughby, A. Liebow, W. Querbes, K. Yucius, T. Nguyen, S. Milstein, M.A. Maier, K.G. Rajeev, and M. Manoharan SiRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes ACS Chem. Biol. 10 2015 1181 1187
68. M.R. Alam, X. Ming, M. Fisher, J.G. Lackey, K.G. Rajeev, M. Manoharan, and R.L. Juliano Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA Bioconjug. Chem. 22 2011 1673 1681
69. L.N. Patel, J.L. Zaro, and W.C. Shen Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives Pharm. Res. 24 2007 1977 1992
70. C. De Coupade, A. Fittipaldi, V. Chagnas, M. Michel, S. Carlier, E. Tasciotti, A. Darmon, D. Ravel, J. Kearsey, M. Giacca, and F. Cailler Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules Biochem. J. 390 2005 407 418
71. T. Holm, H. Raagel, S.E. Andaloussi, M. Hein, M. Mae, M. Pooga, and U. Langel Retro-inversion of certain cell-penetrating peptides causes severe cellular toxicity Biochim. Biophys. Acta 2011 1808 1544 1551
72. H.L.-J.A. Lee, Y. Chen, K.T. Love, A.I. Park, E.D. Karagiannis, A. Sehgal, W. Querbes, C.S. Zurenko, M. Jayaraman, C.G. Peng, K. Charisse, A. Borodovsky, M. Manoharan, J.S. Donahoe, J. Truelove, M. Nahrendorf, R. Langer, and D.G. Anderson Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery Nat. Nanotechnol. 7 2012
73. C. Shen, A.K. Buck, X. Liu, M. Winkler, and S.N. Reske Gene silencing by adenovirus-delivered siRNA FEBS Lett. 539 2003 111 114
74. A. de Fougerolles, H. Vornlocher, J. Maraganore, and J. Lieberman Interfering with disease: a progress report on siRNA therapeutics Nat. Rev. Drug Discov. 6 2007
75. A. Akinc, M. Thomas, A.M. Klibanov, and R. Langer Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis J. Gene Med. 7 2005 657 663
76. C. Pichon, C. Goncalves, and P. Midoux Histidine-rich peptides and polymers for nucleic acids delivery Adv. Drug Deliv. Rev. 53 2001
77. R.E. Vandenbroucke, B.G. De Geest, S. Bonne, M. Vinken, T. Van Haecke, H. Heimberg, E. Wagner, V. Rogiers, S.C. De Smedt, J. Demeester, and N.N. Sanders Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters) J. Gene Med. 10 2008 783 794
78. W. Zauner, M. Ogris, and E. Wagner Polylysine-based transfection systems utilizing receptor-mediated delivery Adv. Drug Deliv. Rev. 30 1998
79. S.M. Noh, S.E. Han, G. Shim, K.E. Lee, C.W. Kim, S.S. Han, Y. Choi, Y.K. Kim, W.K. Kim, and Y.K. Oh Tocopheryl oligochitosan-based self assembling oligomersomes for siRNA delivery Biomaterials 32 2011 849 857
80. F. Takeshita, Y. Minakuchi, S. Nagahara, K. Honma, H. Sasaki, K. Hirai, T. Teratani, N. Namatame, Y. Yamamoto, K. Hanai, T. Kato, A. Sano, and T. Ochiya Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo Proc. Natl. Acad. Sci. U. S. A. 102 2005 12177 12182
81. A.J. Convertine, D.S. Benoit, C.L. Duvall, A.S. Hoffman, and P.S. Stayton Development of a novel endosomolytic diblock copolymer for siRNA delivery J. Control Release 133 2009 221 229
82. H. Li, S.S. Yu, M. Miteva, C.E. Nelson, T. Werfel, T.D. Giorgio, and C.L. Duvall Matrix metalloproteinase responsive, proximity-activated polymeric nanoparticles for siRNA delivery Adv. Funct. Mater. 23 2013 3040 3052
83. C.E. Nelson, R.J. Kintzing, A. Hanna, J.M. Shannon, M.K. Gupta, and C.L. Duvall Balancing cationic and hydrophobic content of pegylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo ACS Nano 7 2013 8870 8880
84. H. Li, M. Miteva, K.C. Kirkbride, M.J. Cheng, C.E. Nelson, E.M. Simpson, M.K. Gupta, C.L. Duvall, and T.D. Giorgio Dual mmp7-proximity-activated and folate receptor-targeted nanoparticles for siRNA delivery Biomacromolecules 16 2015 192 201
85. M. Miteva, K.C. Kirkbride, K.V. Kilchrist, T.A. Werfel, H. Li, C.E. Nelson, M.K. Gupta, T.D. Giorgio, and C.L. Duvall Tuning pegylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers Biomaterials 38 2015 97 107
86. B. Ozpolat, A.K. Sood, and G. Lopez-Berestein Liposomal siRNA nanocarriers for cancer therapy Adv. Drug. Deliv. Rev. 66 2014 110 116
87. M.D. Green, A.A. Foster, C.T. Greco, R. Roy, R.M. Lehr, T.H. Epps III, and M.O. Sullivan Catch and release: photocleavable cationic diblock copolymers as a potential platform for nucleic acid delivery Polym. Chem. 5 2014
88. K.L. Kozielski, S.Y. Tzeng, B.A. Hurtado De Mendoza, and J.J. Green Bioreducible cationic polymer-based nanoparticles for efficient and environmentally triggered cytoplasmic siRNA delivery to primary human brain cancer cells ACS Nano 8 2015
89. M.Ø. Andersen, D.Q.S. Le, M. Chen, J.V. Nygaard, M. Kassem, C. Bünger, and J. Kjems Spatially controlled delivery of siRNAs to stem cells in implants generated by multi-component additive manufacturing Adv. Funct. Mater. 23 2013 5599 5607
90. H. Cao, X. Jiang, C. Chai, and S.Y. Chew RNA interference by nanofiber-based siRNA delivery system J. Control Release 144 2010 203 212
91. S.W.K.B. Lee, S. Chen, Y. Shao-Horn, and P.T. Hammond Layer-by-layer assembly of all carbon nanotube ultrathin films for electrochemical applications J. Am. Chem. Soc. 131 2008 671 679
92. X. Zhu, L. Lu, B.L. Currier, A.J. Windebank, and M.J. Yaszemski Controlled release of NFκβ decoy oligonucleotides from biodegradable polymer microparticles Biomaterials 23 2002
93. P.M. Mountziaris, D.C. Sing, S.A. Chew, S.N. Tzouanas, E.D. Lehman, F.K. Kasper, and A.G. Mikos Controlled release of anti-inflammatory siRNA from biodegradable polymeric microparticles intended for intra-articular delivery to the temporomandibular joint Pharm. Res. 28 2011 1370 1384
94. S.J. Lewis, W.J. Irwin, and S. Akhtar Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of p(LA-GA) copolymer microspheres in vitro J. Drug Targets 5 1998
95. S. Akhtar, and K.J. Lewis Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradablepolymer microspheres Int. J. Pharm. 151 1997
96. P. Pradhan, H. Qin, J.A. Leleux, D. Gwak, I. Sakamaki, L.W. Kwak, and K. Roy The effect of combined IL10 siRNA and CPG ODN as pathogen-mimicking microparticles on TH1/TH2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma Biomaterials 35 2014 5491 5504
97. A. Singh, S. Suri, and K. Roy In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells Biomaterials 30 2009 5187 5200
98. P.M. Mountziaris, S.N. Tzouanas, D.C. Sing, P.R. Kramer, F.K. Kasper, and A.G. Mikos Intra-articular controlled release of anti-inflammatory siRNA with biodegradable polymer microparticles ameliorates temporomandibular joint inflammation Acta Biomater. 8 2012 3552 3560
99. E.S. Place, N.D. Evans, and M.M. Stevens Complexity in biomaterials for tissue engineering Nat. Mater. 8 2009
100. R. Vinas-Castells, C. Holladay, A. di Luca, V.M. Diaz, and A. Pandit Snail1 down-regulation using small interfering RNA complexes delivered through collagen scaffolds Bioconjug. Chem. 20 2009
101. D.M. Salvay, M. Zelivyanskaya, and L.D. Shea Gene delivery by surface immobilization of plasmid to tissue-engineering scaffolds Gene Ther. 17 2010 1134 1141
102. S.A. Guelcher Biodegradable polyurethanes: synthesis and applications in regenerative medicine Tissue Eng. Part B Rev. 14 2008 3 17
103. A.E. Hafeman, B. Li, T. Yoshii, K. Zienkiewicz, J.M. Davidson, and S.A. Guelcher Injectable biodegradable polyurethane scaffolds with release of platelet-derived growth factor for tissue repair and regeneration Pharm. Res. 25 2008 2387 2399
104. B. Li, K.V. Brown, J.C. Wenke, and S.A. Guelcher Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model J. Control Release 145 2010 221 230
105. Y. Lei, M. Rahim, Q. Ng, and T. Segura Hyaluronic acid and fibrin hydrogels with concentrated DNA/pei polyplexes for local gene delivery J. Control Release 153 2011 255 261
106. M.O. Andersen, K.A. Howard, S.R. Paludan, F. Besenbacher, and J. Kjems Delivery of siRNA from lyophilized polymeric surfaces Biomaterials 29 2008 506 512
107. Y. Lei, S. Huang, P. Sharif-Kashani, Y. Chen, P. Kavehpour, and T. Segura Incorporation of active DNA/cationic polymer polyplexes into hydrogel scaffolds Biomaterials 31 2010 9106 9116
108. C.E. Nelson, M.K. Gupta, E.J. Adolph, J.M. Shannon, S.A. Guelcher, and C.L. Duvall Sustained local delivery of siRNA from an injectable scaffold Biomaterials 33 2012 1154 1161
109. P.O. Rujitanaroj, Y.C. Wang, J. Wang, and S.Y. Chew Nanofiber-mediated controlled release of siRNA complexes for long term gene-silencing applications Biomaterials 32 2011 5915 5923
110. M.D. Krebs, O. Jeon, and E. Alsberg Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels J. Am. Chem. Soc. 131 2009
111. K. Nguyen, P.N. Dang, and E. Alsberg Functionalized, biodegradable hydrogels for control over sustained and localized siRNA delivery to incorporated and surrounding cells Acta Biomater. 9 2013 4487 4495
112. M.Ø. Andersen, D.Q.S. Le, M. Chen, J.V. Nygaard, M. Kassem, C. Bünger, and J. Kjems Spatially controlled delivery of siRNAs to stem cells in implants generated by multi-component additive manufacturing Adv Funct Mater. 23 2013 5599 5607
113. A. Galperin, T.J. Long, S. Garty, and B.D. Ratner Synthesis and fabrication of a degradable poly(n-isopropyl acrylamide) scaffold for tissue engineering applications J. Biomed. Mater. Res. A. 101 2013 775 786
114. M.K. Gupta, J.R. Martin, T.A. Werfel, T. Shen, J.M. Page, and C.L. Duvall Cell protective, ABC triblock polymer-based thermoresponsive hydrogels with ROS-triggered degradation and drug release J. Am. Chem. Soc. 136 2014 14896 14902
115. R.V. Joshi, C.E. Nelson, K.M. Poole, M.C. Skala, and C.L. Duvall Dual pH- and temperature-responsive microparticles for protein delivery to ischemic tissues Acta Biomater. 9 2013 6526 6534
116. Z. Ma, D.M. Nelson, Y. Hong, and W.R. Wagner Thermally responsive injectable hydrogel incorporating methacrylate-polylactide for hydrolytic lability Biomacromolecules 11 2010 1873 1881
117. L.E. Strong, S.N. Dahotre, and J.L. West Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery J. Control Release 178 2014 63 68
118. H.Y. Yang, R.J. van Ee, K. Timmer, E.G. Craenmehr, J.H. Huang, F.C. Oner, W.J. Dhert, A.H. Kragten, N. Willems, G.C. Grinwis, M.A. Tryfonidou, N.E. Papen-Botterhuis, and L.B. Creemers A novel injectable thermoresponsive and cytocompatible gel of poly(n-isopropylacrylamide) with layered double hydroxides facilitates siRNA delivery into chondrocytes in 3d culture Acta Biomater. 2015
119. S. Ishii, J. Kaneko, and Y. Nagasaki Dual stimuli-responsive redox-active injectable gel by polyion complex based flower micelles for biomedical applications Macromolecules 48 2015 3088 3094
120. L.N. Borgheti-Cardoso, L.V. Depieri, S.A. Kooijmans, H. Diniz, R.A. Calzzani, F.T. Vicentini, R. van der Meel, M.C. Fantini, M.M. Iyomasa, R.M. Schiffelers, and M.V. Bentley An in situ gelling liquid crystalline system based on monoglycerides and polyethylenimine for local delivery of siRNAs Eur. J. Pharm. Sci. 74 2015 103 117
121. Y.M. Kim, M.R. Park, and S.C. Song An injectable cell penetrable nano-polyplex hydrogel for localized siRNA delivery Biomaterials 34 2013 4493 4500
122. K. Li, L. Feng, J. Shen, Q. Zhang, Z. Liu, S.T. Lee, and J. Liu Patterned substrates of nano-graphene oxide mediating highly localized and efficient gene delivery ACS Appl. Mater. Int. 6 2014 5900 5907
123. J. Min, R.D. Braatz, and P.T. Hammond Tunable staged release of therapeutics from layer-by-layer coatings with clay interlayer barrier Biomaterials 35 2014 2507 2517
124. B.S. Kim, R.C. Smith, Z. Poon, and P.T. Hammond MAD (multiagent delivery) nanolayer: delivering multiple therapeutics from hierarchically assembled surface coatings Langmuir 25 2009 14086 14092
125. J.S.N. Hong, A.C. Drake, P.C. DeMuth, J.B. Lee, J. Chen, and P.T. Hammond Graphene multilayers as gates for multi-week sequential release of proteins from surfaces ACS Nano 6 2012
126. S. Castleberry, M. Wang, and P.T. Hammond Nanolayered siRNA dressing for sustained localized knockdown ACS Nano. 7 2013
127. V.D. Thanik, M.R. Greives, O.Z. Lerman, N. Seiser, W. Dec, C.C. Chang, S.M. Warren, J.P. Levine, and P.B. Saadeh Topical matrix-based siRNA silences local gene expression in a murine wound model Gene Ther. 14 2007
128. M. Wetterau, F. George, A. Weinstein, P.D. Nguyen, J.P. Tutela, D. Knobel, B.O. Cohen, S.M. Warren, and P.B. Saadeh Topical prolyl hydroxylase domain-2 silencing improves diabetic murine wound closure Wound Repair Regen. 19 2011 481 486
129. P.D. Nguyen, J.P. Tutela, V.D. Thanik, D. Knobel, R.J. Allen Jr., C.C. Chang, J.P. Levine, S.M. Warren, and P.B. Saadeh Improved diabetic wound healing through topical silencing of p53 is associated with augmented vasculogenic mediators Wound Repair Regen. 18 2010 553 559
130. J.W. Lee, J.P. Tutela, R.A. Zoumalan, V.D. Thanik, P.D. Nguyen, L. Varjabedian, S.M. Warren, and P.B. Saadeh Inhibition of SMAD3 expression in radiation-induced fibrosis using a novel method for topical transcutaneous gene therapy Arch. Otolaryngol. Head Neck Surg. 136 2010
131. S.Y. Wu, H.I. Chang, M. Burgess, and N.A. McMillan Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system J. Control Release 155 2011 418 426
132. D. Ollitrault, F. Legendre, C. Drougard, M. Briand, H. Benateau, D. Goux, H. Chajra, L. Poulain, D. Hartmann, D. Vivien, V. Shridhar, A. Baldi, F. Mallein-Gerin, K. Boumediene, M. Demoor, and P. Galera BMP-2, hypoxia, and COL1a1/HTRA1 siRNAs favor neo-cartilage hyaline matrix formation in chondrocytes Tissue Eng. C Meth. 2014
133. H.D. Han, E.M. Mora, J.W. Roh, M. Nishimura, S.J. Lee, R.L. Stone, M. Bar-Eli, G. Lopez-Berestein, and A.K. Sood Chitosan hydrogel for localized gene silencing Cancer Biol. Ther. 11 2011 839 845
134. Z. Ma, C. Yang, W. Song, Q. Wang, J. Kjems, and S. Gao Chitosan hydrogel as siRNA vector for prolonged gene silencing J. Nanobiotechnol. 12 2014
135. H. Hartmann, S. Hossfeld, B. Schlosshauer, U. Mittnacht, A.P. Pego, M. Dauner, M. Doser, D. Stoll, and R. Krastev Hyaluronic acid/chitosan multilayer coatings on neuronal implants for localized delivery of siRNA nanoplexes J. Control Release 168 2013 289 297
136. S. Hossfeld, A. Nolte, H. Hartmann, M. Recke, M. Schaller, T. Walker, J. Kjems, B. Schlosshauer, D. Stoll, H.P. Wendel, and R. Krastev Bioactive coronary stent coating based on layer-by-layer technology for siRNA release Acta Biomater. 9 2013 6741 6752
137. M.T. Vandegrift, C. Szpalski, D. Knobel, A. Weinstein, M. Ham, O. Ezeamuzie, S.M. Warren, and P.B. Saadeh Acellular dermal matrix-based gene therapy augments graft incorporation J. Surg. Res. 195 2015 360 367
138. N. Segovia, M. Pont, N. Oliva, V. Ramos, S. Borros, and N. Artzi Hydrogel doped with nanoparticles for local sustained release of siRNA in breast cancer Adv. Healthc Mater. 4 2015 271 280
139. T. Manaka, A. Suzuki, K. Takayama, Y. Imai, H. Nakamura, and K. Takaoka Local delivery of siRNA using a biodegradable polymer application to enhance BMP-induced bone formation Biomaterials 32 2011 9642 9648
140. P.O. Rujitanaroj, B. Jao, J. Yang, F. Wang, J.M. Anderson, J. Wang, and S.Y. Chew Controlling fibrous capsule formation through long-term down-regulation of collagen type I (COL1a1) expression by nanofiber-mediated siRNA gene silencing Acta Biomater. 9 2013 4513 4524
141. W.C. Low, P.O. Rujitanaroj, D.K. Lee, P.B. Messersmith, L.W. Stanton, E. Goh, and S.Y. Chew Nanofibrous scaffold-mediated REST knockdown to enhance neuronal differentiation of stem cells Biomaterials 34 2013 3581 3590
142. M.O. Andersen, J.V. Nygaard, J.S. Burns, M.K. Raarup, J.R. Nyengaard, C. Bunger, F. Besenbacher, K.A. Howard, M. Kassem, and J. Kjems SiRNA nanoparticle functionalization of nanostructured scaffolds enables controlled multilineage differentiation of stem cells Mol. Ther. 18 2010 2018 2027
143. J. Zoldan, A.K. Lytton-Jean, E.D. Karagiannis, K. Deiorio-Haggar, L.M. Bellan, R. Langer, and D.G. Anderson Directing human embryonic stem cell differentiation by non-viral delivery of siRNA in 3D culture Biomaterials 32 2011 7793 7800
144. K. Takayama, A. Suzuki, T. Manaka, S. Taguchi, Y. Hashimoto, Y. Imai, S. Wakitani, and K. Takaoka RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro J. Bone Miner. Metab. 27 2009 402 411
145. E. Gazzerro, A. Smerdel-Ramoya, S. Zanotti, L. Stadmeyer, D. Durant, A.N. Economides, and E. Canalis Conditional deletion of gremlin causes a transient increase in bone formation and bone mass J. Biol. Chem. 282 2007 31549 31557
146. X. Zhang, A. Kovtun, C. Mendoza-Palomares, M. Oulad-Abdelghani, F. Fioretti, S. Rinckenbach, D. Mainard, M. Epple, and N. Benkirane-Jessel SiRNA-loaded multi-shell nanoparticles incorporated into a multilayered film as a reservoir for gene silencing Biomaterials 31 2010 6013 6018
147. N. Kinouchi, Y. Ohsawa, N. Ishimaru, H. Ohuchi, Y. Sunada, Y. Hayashi, Y. Tanimoto, K. Moriyama, and S. Noji Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass Gene Ther. 15 2008 1126 1130
148. E. Kawakami, N. Kawai, N. Kinouchi, H. Mori, Y. Ohsawa, N. Ishimaru, Y. Sunada, S. Noji, and E. Tanaka Local applications of myostatin-siRNA with atelocollagen increase skeletal muscle mass and recovery of muscle function PloS One 8 2013 e64719
149. P. Lu, G.R. Zhang, X.H. Song, X.H. Zou, L.L. Wang, and H.W. Ouyang Col v siRNA engineered tenocytes for tendon tissue engineering PloS One 6 2011
150. L.X. Chen, L. Lin, H.J. Wang, X.L. Wei, X. Fu, J.Y. Zhang, and C.L. Yu Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated nf-kappabp65-specific siRNA Osteoarthr. Cartilage 16 2008 174 184
151. L. Dong, Z. Huang, X. Cai, J. Xiang, Y.A. Zhu, R. Wang, J. Chen, and J. Zhang Localized delivery of antisense oligonucleotides by cationic hydrogel suppresses TNF-alpha expression and endotoxin-induced osteolysis Pharm. Res. 28 2011 1349 1356
152. L.C.H. Zheng, S. Chen, T. Tang, W. Fu, L. Huang, D. Ho, K. Chow, Y. Wang, J.F. Griffith, W. He, H. Zhou, D. Zhao, G. Zhang, X. Wang, and L. Qin Blockage of Src by specific siRNA as a novel therapeutic strategy to prevent destructive repair in steroid-associated osteonecrosis in rabbits J. Bone Miner. Res. 2015
153. X. Chu, H. You, X. Yuan, W. Zhao, W. Li, and X. Guo Protective effect of lentivirus-mediated siRNA targeting ADAMTS-5 on cartilage degradation in a rat model of osteoarthritis Int. J. Mol. Med. 31 2013 1222 1228
154. Y. Pi, X. Zhang, Z. Shao, F. Zhao, X. Hu, and Y. Ao Intra-articular delivery of anti-HIF-2alpha siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice Gene Ther. 22 2015 439 448
155. H. Brem, and M. Tomic-Canic Cellular and molecular basis of wound healing in diabetes J. Clin. Invest. 117 2007 1219 1222
156. T. Tokatlian, C. Cam, and T. Segura Non-viral DNA delivery from porous hyaluronic acid hydrogels in mice Biomaterials 35 2014 825 835
157. J.H. Jang, C.B. Rives, and L.D. Shea Plasmid delivery in vivo from porous tissue-engineering scaffolds: transgene expression and cellular transfection Mol. Ther. 12 2005 475 483
158. A. Alfranca VEGF therapy: a timely retreat Cardiovasc. Res. 83 2009 611 612
159. Y. Brudno, A.B. Ennett-Shepard, R.R. Chen, M. Aizenberg, and D.J. Mooney Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors Biomaterials 34 2013 9201 9209
160. S.K. Cheema, E. Chen, L.D. Shea, and A.B. Mathur Regulation and guidance of cell behavior for tissue regeneration via the siRNA mechanism Wound Repair Regen. 15 2007 286 295
161. G.L. Semenza Regulation of oxygen homeostasis by hypoxia-inducible factor 1 Physiology 24 2009 97 106
162. H. Agis, G. Watzek, and R. Gruber Prolyl hydroxylase inhibitors increase the production of vascular endothelial growth factor by periodontal fibroblasts J. Periodontal Res. 47 2012 165 173
163. M. Mazzone, D. Dettori, R. Leite de Oliveira, S. Loges, T. Schmidt, B. Jonckx, Y.M. Tian, A.A. Lanahan, P. Pollard, C. Ruiz de Almodovar, F. De Smet, S. Vinckier, J. Aragones, K. Debackere, A. Luttun, S. Wyns, B. Jordan, A. Pisacane, B. Gallez, M.G. Lampugnani, E. Dejana, M. Simons, P. Ratcliffe, P. Maxwell, and P. Carmeliet Heterozygous deficiency of phd2 restores tumor oxygenation and inhibits metastasis via endothelial normalization Cell 136 2009 839 851
164. Z. Wang, Z. Gao, Y. Shi, Y. Sun, Z. Lin, H. Jiang, T. Hou, Q. Wang, X. Yuan, X. Zhu, H. Wu, and Y. Jin Inhibition of smad3 expression decreases collagen synthesis in keloid disease fibroblasts J. Plast. Reconstr. Aesthet. 60 2007 1193 1199
165. J.S. Huang, Y. Wang, T. Ling, S. Chuang, F.E. Johnson, and S.S. Huang Synthetic TGF-β antagonist accelerates wound healing and reduces scarring FASEB J. 16 2002
166. H. Nakamura, S.S. Siddiqui, X. Shen, A.B. Malik, J.S. Pulido, N.M. Kumar, and B.Y. Yue RNA interference targeting transforming growth factor-β type II receptor suppresses ocular inflammation and fibrosis Mol. Vis. 10 2004
167. S. Sriram, P. Robinson, L. Pi, A.S. Lewin, and G. Schultz Triple combination of siRNAs targeting TGFbeta1, TGFbetaR2, and CTGF enhances reduction of collagen I and smooth muscle actin in corneal fibroblasts Invest. Ophthalmol. Vis. Sci. 54 2013 8214 8223
168. C. Zhang, X. Kong, C. Liu, Z. Liang, H. Zhao, W. Tong, G. Ning, W. Shen, L. Yao, and S. Feng Erk2 small interfering RNAs prevent epidural fibrosis via the efficient inhibition of collagen expression and inflammation in laminectomy rats Biochem. Biophys. Res. Commun. 444 2014 395 400
169. H. Takahashi, Y. Wang, and D.W. Grainger Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation J. Control Release 147 2010 400 407
170. M. Jakobsen, K. Stenderup, C. Rosada, B. Moldt, S. Kamp, T.N. Dam, T.G. Jensen, and J.G. Mikkelsen Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model Mol. Ther. 17 2009 1743 1753
171. Y. Zhang, P. Cristofaro, R. Silbermann, O. Pusch, D. Boden, T. Konkin, V. Hovanesian, P.R. Monfils, M. Resnick, S.F. Moss, and B. Ramratnam Engineering mucosal RNA interference in vivo Mol. Ther. 14 2006 336 342
172. Z. Huang, and M.R. King An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation Gene Ther. 16 2009 1271 1282
173. S. Goldman, K. Zadina, T. Moritz, T. Ovitt, G. Sethi, J.G. Copeland, L. Thottapurathu, B. Krasnicka, N. Ellis, R.J. Anderson, W. Henderson, and V.A.C.S. Group Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a department of veterans affairs cooperative study J. Am. Coll. Cardiol. 44 2004 2149 2156
174. A. San Juan, M. Bala, H. Hlawaty, P. Portes, R. Vranckx, L.J. Feldman, and D. Letourneur Development of a functionalized polymer for stent coating in the arterial delivery of small interfering RNA Biomacromolecules 10 2009
175. B.C. Evans, K.M. Hocking, M.J. Osgood, I. Voskresensky, J. Dmowska, K.V. Kilchrist, C.M. Brophy, and C.L. Duvall MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia Sci. Transl. Med. 7 2015
176. V.J.R.C. Dzau, and D.G. Sedding Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies Nat. Med. 8 2002
177. C.S. Nabzdyk, M.C. Chun, H.S. Oliver-Allen, S.G. Pathan, M.D. Phaneuf, J.O. You, L.K. Pradhan-Nabzdyk, and F.W. LoGerfo Gene silencing in human aortic smooth muscle cells induced by pei-siRNA complexes released from dip-coated electrospun poly(ethylene terephthalate) grafts Biomaterials 35 2014 3071 3079
178. D. Palliser, D. Chowdhury, Q.Y. Wang, S.J. Lee, R.T. Bronson, D.M. Knipe, and J. Lieberman An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection Nature 439 2006 89 94
179. K.A. Woodrow, Y. Cu, C.J. Booth, J.K. Saucier-Sawyer, M.J. Wood, and W.M. Saltzman Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA Nat. Mater. 8 2009
180. Y. Kim, M. Park, and S. Song Injectable polyplex hydrogel for localized and long-term delivery of siRNA ACS Nano 6 2012
181. E.Z. Khvalevsky, R. Gabai, I.H. Rachmut, E. Horwitz, Z. Brunschwig, A. Orbach, A. Shemi, T. Golan, A.J. Domb, E. Yavin, H. Giladi, L. Rivkin, A. Simerzin, R. Eliakim, A. Khalaileh, A. Hubert, M. Lahav, Y. Kopelman, E. Goldin, A. Dancour, Y. Hants, S. Arbel-Alon, R. Abramovitch, A. Shemi, and E. Galun Mutant KRAS is a druggable target for pancreatic cancer Proc. Natl. Acad. Sci. U. S. A. 110 2013 20723 20728
182. S. Eser, A. Schnieke, G. Schneider, and D. Saur Oncogenic kras signalling in pancreatic cancer Br. J. Cancer 111 2014 817 822
183. M. Nakamura, J. Jo, Y. Tabata, and O. Ishikawa Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (alopecia areata) in a C3H/HEJ mouse model Am. J. Pathol. 172 2008 650 658
184. P. Ritprajak, M. Hashiguchi, and M. Azuma Topical application of cream-emulsified CD86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells Mol. Ther. 16 2008 1323 1330
185. D. Abraham Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSC? Rheumatology 47 Suppl. 5 2008 v8 v9
186. K. Bedelbaeva, A. Snyder, D. Gourevitch, L. Clark, X.M. Zhang, J. Leferovich, J.M. Cheverud, P. Lieberman, and E. Heber-Katz Lack of p21 expression links cell cycle control and appendage regeneration in mice Proc. Natl. Acad. Sci. U. S. A. 107 2010 5845 5850
187. Y. Zhou, X. Guan, M. Yu, X. Wang, W. Zhu, C. Wang, M. Yu, and H. Wang Angiogenic/osteogenic response of bmmscs on bone-derived scaffold: effect of hypoxia and role of PI3K/AKT-mediated VEGF-VEGFR pathway Biotechnol. J. 9 2014 944 953
188. Y.M. Kim, and S.C. Song Targetable micelleplex hydrogel for long-term, effective, and systemic siRNA delivery Biomaterials. 35 2014 7970 7977
189. S.P. Patil, S.H. Kim, J.R. Jadhav, J.H. Lee, E.M. Jeon, K.T. Kim, and B.H. Kim Cancer-specific gene silencing through therapeutic siRNA delivery with B vitamin-based nanoassembled low-molecular-weight hydrogelators Bioconjug. Chem. 2014
190. C.P. Neff, J. Zhou, L. Remling, J. Kuruvilla, J. Zhang, H. Li, D.D. Smith, P. Swiderski, J.J. Rossi, and R. Akkina An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4 + t cell decline in humanized mice Sci. Transl. Med. 3 2011
191. H.A. Kim, K. Nam, and S.W. Kim Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery Biomaterials 35 2014 7543 7552
192. M.R. Zamora, M. Budev, M. Rolfe, J. Gottlieb, A. Humar, J. Devincenzo, A. Vaishnaw, J. Cehelsky, G. Albert, S. Nochur, J.A. Gollob, and A.R. Glanville RNA interference therapy in lung transplant patients infected with respiratory syncytial virus Am. J. Respir. Crit. Care 183 2011 531 538
193. P.K. Kaiser, R.C. Symons, S.M. Shah, E.J. Quinlan, H. Tabandeh, D.V. Do, G. Reisen, J.A. Lockridge, B. Short, R. Guerciolini, and Q.D. Nguyen SiRNA-027 study I. RNAi-based treatment for neovascular age-related macular degeneration by siRNA-027 Am. J. Opthalmol. 150 2010 33 39 e32
194. S.A. Leachman, R.P. Hickerson, M.E. Schwartz, E.E. Bullough, S.L. Hutcherson, K.M. Boucher, C.D. Hansen, M.J. Eliason, G.S. Srivatsa, D.J. Kornbrust, F.J. Smith, W.I. McLean, L.M. Milstone, and R.L. Kaspar First-in-human mutation-targeted siRNA phase ib trial of an inherited skin disorder Mol. Ther. 18 2010 442 446
195. J.D. Thompson Clinical development of synthetic siRNA therapeutics Drug Discov. Today 10 2013 e133 e138
196. R. Kanasty, J.R. Dorkin, A. Vegas, and D. Anderson Delivery materials for siRNA therapeutics Nat. Mater. 12 2013 967 977
197. N.M. Snead, and J.J. Rossi RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics Nucleic Acid Ther. 22 2012 139 146
198. M.J. Tolentino, A.J. Brucker, J. Fosnot, G.S. Ying, I.H. Wu, G. Malik, S. Wan, and S.J. Reich Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization Retina-J. Ret. Vit. Dis. 24 2004
199. N.S. Dejneka, S. Wan, O.S. Bond, D.J. Kornbrust, and S.J. Reich Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes Mol Vis. 14 2008
200. Open label study for the evaluation of tolerability of five dose levels of Cand5 (OPKO Health, Inc.) Retrieved from http://clinicaltrials.gov/ct2 2008 (Identification No. NCT00722384)
201. Safety and efficacy study of small interfering ribonucleic acid (RNA) molecule (Cand5) to treat wet age-related macular degeneration (OPKO Health, Inc.) Retrieved from http://clinicaltrials.gov/ct2 2008 (Identification No. NCT00259753)
202. Safety and efficacy study of small interfering RNA molecule (Cand5) to treat diabetic macular edema (OPKO Health, Inc.) Retrieved from http://clinicaltrials.gov/ct2 2008 (Identification No. NCT00306904)
203. Safety & efficacy study evaluating the combination of bevasiranib & lucentis therapy in wet AMD (COBALT) (OPKO Health, Inc.) Retrieved from http://clinicaltrials.gov/ct2 2014 (Identification No. NCT00499590)
204. A dose escalation trial of an intravitreal injection of SiRNA-027 in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) (Allergan) Retrieved from http://clinicaltrials.gov/ct2 2008 (Identification No. NCT00363714)
205. A Study using intravitreal injections of a small interfering RNA in patients with age-related macular degeneration (Allergan) Retrieved from http://clinicaltrials.gov/ct2 2015 (Identification No. NCT00395057)
206. Study of PF-04523655 (REDD14NP) in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (Wet AMD) (Quark Pharmaceuticals) Retrieved from http://clinicaltrials.gov/ct2 2012 (Identification No. NCT00725686)
207. Q.D. Nguyen, R.A. Schachar, C.I. Nduaka, M. Sperling, A.S. Basile, K.J. Klamerus, K. Chi-Burris, E. Yan, D.A. Paggiarino, I. Rosenblatt, A. Khan, R. Aitchison, S.S. Erlich, and P.F.S. Group Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients Eye. 26 2012 1099 1105
208. Study evaluating efficacy and safety of PF-04523655 versus laser in subjects with diabetic macular edema (DEGAS) (Quark Pharmaceuticals) Retrieved from http://clinicaltrials.gov/ct2 2012 (Identification No. NCT00701181)
209. Phase II open label multicenter study for age related macular degeneration comparing PF-04523655 versus lucentis in the treatment of subjects with CNV (MONET Study). (Quark Pharmaceuticals) Retrieved from http://clinicaltrials.gov/ct2 2012 (Identification No. NCT00713518)
210. PF-04523655 dose escalation study, and evaluation of PF-04523655 with/without ranibizumab in diabetic macular edema (DME) (MATISSE) (Quark Pharmaceuticals) Retrieved from http://clinicaltrials.gov/ct2 2015 (Identification No. NCT01445899)
211. Intranasal ALN-RSV01 administered to adult volunteers experimentally inoculated with respiratory syncytial virus (Alnylam Pharmaceuticals) Retrieved from http://clinicaltrials.gov/ct2 2007 (Identification No. NCT00496821)
212. J. DeVincenzo, J.E. Cehelsky, R. Alvarez, S. Elbashir, J. Harborth, I. Toudjarska, L. Nechev, V. Murugaiah, A. Van Vliet, A.K. Vaishnaw, and R. Meyers Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV) Antivir. Res. 77 2008 225 231
213. Phase 2b study of ALN-RSV01 in lung transplant patients infected with respiratory syncytial virus (RSV) (Alnylam Pharmaceuticals) Retrieved from http://clinicaltrials.gov/ct2 2012 (Identification No. NCT01065935)
214. Phase 2 study of ALN-RSV01 in lung transplant patients infected with respiratory syncytial virus (RSV). (Alnylam Pharmaceuticals) Retrieved from http://clinicaltrials.gov/ct2 2009 (Identification No. NCT00658086)
215. Study of TD101, a small interfering RNA (siRNA) designed for treatment of pachyonychia congenita (Pachyonychia Congenita Project) Retrieved from http://clinicaltrials.gov/ct2 2008 (Identification No. NCT00716014)
216. Tolerance and effect on intraocular pressure after administration of SYL040012 (Sylentis, S.A.) Retrieved from http://clinicaltrials.gov/ct2 2010 (Identification No. NCT00990743)
217. J. Moreno-Montanes, B. Sadaba, V. Ruz, A. Gomez-Guiu, J. Zarranz, M.V. Gonzalez, C. Paneda, and A.I. Jimenez Phase I clinical trial of SYL040012, a small interfering RNA targeting beta-adrenergic receptor 2, for lowering intraocular pressure Mol. Ther. 22 2014 226 232
218. SYL040012. tolerance and effect on intraocular pressure in subjects with intraocular pressure (IOP) >=21 mm Hg (Sylentis, S.A.) Retrieved from http://clinicaltrials.gov/ct2 2012 (Identification No. NCT01227291)
219. Dose finding clinical trial with SYL040012 to evaluate the tolerability and effect on intraocular pressure in subjects with ocular hypertension or open angle glaucoma (Sylentis, S.A.) Retrieved from http://clinicaltrials.gov/ct2 2013 (Identification No. NCT01739244)
220. SYL040012, treatment for open angle glaucoma (SYLTAG) (Sylentis, S.A.) Retrieved from http://clinicaltrials.gov/ct2 2015 (Identification No. NCT02250612)
221. Z. Ahmed, H. Kalinski, M. Berry, M. Almasieh, H. Ashush, N. Slager, A. Brafman, I. Spivak, N. Prasad, I. Mett, E. Shalom, E. Alpert, A. Di Polo, E. Feinstein, and A. Logan Ocular neuroprotection by siRNA targeting caspase-2 Cell Death Dis. 2 2011 e173
222. Safety study of a single IVT injection of QPI-1007 in chronic optic nerve atrophy and recent onset NAION patients (Quark Pharmaceuticals) Retrieved from http://clinicaltrials.gov/ct2 2013 (Identification No. NCT01064505)
223. Phase IIA double-masked randomized sham-controlled trial of QPI-1007 delivered by a single intravitreal injection to subjects with acute primary angle-closure glaucoma (APACG) (Quark Pharmaceuticals) Retrieved from http://clinicaltrials.gov/ct2 2015 (Identification No. NCT01965106)
224. Phase I - escalating dose study of siG12D LODER (Local Drug EluteR) in patients with locally advanced adenocarcinoma of the pancreas, and a single dose study of siG12D LODER (Local Drug EluteR) in patients with non-operable adenocarcinoma of the pancreas (Silenseed Ltd) Retrieved from http://clinicaltrials.gov/ct2 2014 (Identification No. NCT01188785)
225. A phase II study of siG12D LODER in combination with chemotherapy in patients with unresectable locally advanced pancreatic cancer (Silenseed Ltd) Retrieved from http://clinicaltrials.gov/ct2 2015 (Identification No. NCT01676259)
226. Study to evaluate the ocular tolerance of SYL1001 in healthy volunteers (Sylentis, S.A.) Retrieved from http://clinicaltrials.gov/ct2 2012 (Identification No. NCT01438281)
227. Pilot study to evaluate SYL1001 safety and effect in patients with ocular pain (Sylentis, S.A.) Retrieved from http://clinicaltrials.gov/ct2 2015 (Identification No. NCT01776658)